These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 21480946)

  • 21. Anaphylaxis after rechallenge with abacavir.
    Walensky RP; Goldberg JH; Daily JP
    AIDS; 1999 May; 13(8):999-1000. PubMed ID: 10371187
    [No Abstract]   [Full Text] [Related]  

  • 22. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 23. The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome.
    Fodor J; Riley BT; Kass I; Buckle AM; Borg NA
    Sci Rep; 2019 Jul; 9(1):10523. PubMed ID: 31324847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual clinical presentation of hypersensitivity reaction to abacavir.
    Aquilina C; Mularczyk M; Lucas F; Viraben R
    AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198
    [No Abstract]   [Full Text] [Related]  

  • 25. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 26. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
    Bellagamba R; Tommasi C; De Marco M; Narciso P
    J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
    [No Abstract]   [Full Text] [Related]  

  • 27. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 28. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiretroviral-induced toxiderma in HIV-infected patients].
    Caumes E; Bossi P; Katlama C; Bricaire F
    Presse Med; 2003 Sep; 32(28):1325-33. PubMed ID: 14506444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetics and the potential for predictive tests in adverse drug reactions.
    Pirmohamed M
    Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding drug hypersensitivity: what to look for when prescribing abacavir.
    Hetherington S
    AIDS Read; 2001 Dec; 11(12):620-2. PubMed ID: 11806176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abacavir warning.
    AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacogenetics of hypersensitivity drug reactions.
    Negrini S; Becquemont L
    Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
    Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
    Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 39. A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
    Shapiro M; Ward KM; Stern JJ
    AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agranulocytosis and fever seven weeks after starting abacavir.
    Sankatsing SU; Prins JM
    AIDS; 2001 Dec; 15(18):2464-5. PubMed ID: 11774836
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.